| metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||||
| mNSCLC - L1 - PDL1 positive | non squamous - mNSCLC - L1 - all population | non squamous - mNSCLC - L1 - Wild Type (WT) | squamous - mNSCLC - L1 - all population | mNSCLC - L2 - all population | mNSCLC - L2 - PDL1 positive | |
| atezolizumab based treatment | ||||||
| atezolizumab alone | IMpower-110 ... IMpower-110 ... IMpower-110 ... | OAK ... POPLAR | OAK ... | |||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | IMpower-150 ... | IMpower-150 ... IMpower-150 ... | ||||
| atezolizumab plus carboplatin plus nab-paclitaxel | IMpower-130 ... | IMpower-130 ... | IMpower-131 ... | |||
| atezolizumab plus carboplatin plus paclitaxel | IMpower-150 ... | IMpower-131 ... | ||||
| atezolizumab plus pemetrexed and platin | IMpower-132 ... | |||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
